Objective
Vaccine candidates are emerging but the time and cost of TB clinical trials prohibits their evaluation. Surrogate markers are needed. Cells from carefully followed up contacts who do or do not develop disease are being studied forcytokine expression by RT-PCR in 3 African centres. VACSIS will add a 4th centre, upgrade technology to real time RT-PCR, and study markers of apoptosis that play a role in immune response regulation in TB. Meanwhile patients TB strains will by typed for polymorphisms in DNA repair genes, and this will be related to disease severity, transmission and immunology
Fields of science
Topic(s)
Data not availableCall for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
W1P 6DB London
United Kingdom
See on map
Participants (5)
2003 Addis Abeba
See on map
75724 Paris
See on map
101 Antananarivo
See on map
2300 Koepenhagen
See on map
10101 Lusaka
See on map